< Back to Press
Mersana Therapeutics Named a "Fierce 15"
Biotech Company for 2012
September 19, 2012 – Mersana Therapeutics, Inc., a
biopharmaceutical company developing its Fleximer® antibody-drug
conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates,
announced today that the editors of FierceBiotech have selected the Company as
one of the Fierce 15 for 2012, designating it as one of the most promising
private companies in the biotechnology industry. Every year FierceBiotech
evaluates hundreds of private companies for its annual Fierce 15 list, which is
based on a variety of factors such as the strength of its technology,
partnerships, venture backers and a competitive market position.
"Mersana's Fleximer platform is clinically validated and now offers a new
technology for generating antibody-drug conjugates, one of the hottest fields
in drug development today," says FierceBiotech Editor Ryan McBride. "The
Company's fresh round of financing led by NEA and earlier partnership with Endo
Pharmaceuticals should help propel its antibody-drug conjugates toward the
clinic in the years ahead. We'll be watching its progress."
"We are honored to be recognized as a Fierce 15 company, as we continue to
advance our drug pipeline and Fleximer-based platform initiatives internally
and through collaborations," said Nicholas Bacopoulos, Ph.D., President and
Chief Executive Officer of Mersana. "With continued support from our partners
and investors, we are developing next-generation drug conjugates to bring
patients new therapeutic options with tremendous potential."
The 2012 Fierce 15 companies will be recognized today at the BioPharm America
conference in Boston. A complete list of "Fierce 15" companies – the online
newsletter's tenth annual selection – is available online at www.fiercebiotech.com.
Mersana engineers novel drug conjugates that maximize the
potential of new and established therapeutic classes. Utilizing its proprietary
technology, which is comprised of the Fleximer® polymer and a
broad array of customizable linker chemistries, Mersana is developing a
portfolio of next-generation antibody-drug conjugates (ADCs) with superior
properties not found with other ADC technologies. Mersana is currently working
with a number of top Pharma companies to develop next generation Fleximer-ADCs
and most recently announced a $270 million collaboration with Endo
Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of
next-generation drugs with best-in-class potential to address unmet needs and
improve patient outcomes in multiple oncology indications. Mersana was founded
by PureTech Ventures, LLC and a group of leading academics and clinicians.
Fleximer® is a trademark of Mersana Therapeutics,
MacDougall Biomedical Communications
781 235 3060